Synthetic antibodies that could transform drug development


What if you could design something that acts like an antibody, but cheaper, more stable, and made entirely with chemistry?

Two LACDR researchers, Sebastian Pomplun and Matthias Barz, teamed up to do just that. By merging peptide synthesis with polymer chemistry, they developed synthetic molecules that mimic the size, shape, and function of antibodies, without the cold storage, high production costs, or immune side effects.

These ‘bottlebrush-like’ nanoscale particles are tough, modular, and ready for next-gen therapies. The concept worked from the very first experiment. The potential? Faster drug development, better patient access, and new pathways for targeting disease.

Read the full story here.


  • SpectaCell raises €6 million to accelerate drug development

    For the Leiden Bio Science Park, it is great to see SpectaCell connecting its technology with the biotech ecosystem here in Leiden. SpectaCell will combine its technology development and cell analysis in Ghent with further validation and application within the…

  • LUMC opens dedicated CAR-T department

    Leiden University Medical Center (LUMC) has opened a dedicated department for CAR-T cell therapy, bringing care, research and expertise in this rapidly developing field together in one place. The new department, officially opened on 24 September, marks another step in…